Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.54 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.52 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25278732 | 0.97 | ESR1 (0.52) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL25231397 | 0.95 | ESR1 (0.52) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL25708309 | 0.91 | ESR1 (0.50) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL16012922 | 0.88 | ESR1 (0.45) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL21300622 | 0.88 | ESR1 (0.45) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL16012923 | 0.88 | ESR1 (0.45) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL25231392 | 0.86 | CYP2D6 (0.55) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL22503893 | 0.86 | MGLL (0.45) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL16013504 | 0.86 | MGLL (0.45) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL16013505 | 0.86 | MGLL (0.45) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452930-A1 | IONIZABLE AMINE AND ESTER LIPIDS AND LIPID NANOPARTICLES | Beam Therapeutics Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240335543-A1 | IONIZABLE AMINE AND ESTER LIPIDS AND LIPID NANOPARTICLES | BEAM THERAPEUTICS INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2023121970-A1 | IONIZABLE AMINE AND ESTER LIPIDS AND LIPID NANOPARTICLES | BEAM THERAPEUTICS INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121970-A1 | IONIZABLE AMINE AND ESTER LIPIDS AND LIPID NANOPARTICLES | BEAM THERAPEUTICS INC. (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335543-A1 | IONIZABLE AMINE AND ESTER LIPIDS AND LIPID NANOPARTICLES | PHOSPHO1, SGMS1, SGMS2 | ESR1 1091/4885AKR1C4 3704/4885AKR1C3 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.